NITROLINGUAL (nitroglycerin) by Pfizer is (no), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic gmp) in smooth muscle and other tissues. Approved for coronary artery disease, heart failure. First approved in 1985.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
NITROLINGUAL is a sublingual nitroglycerin aerosol approved in 1985 for acute relief and prevention of angina pectoris and other cardiovascular conditions. It works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic GMP in smooth muscle, leading to vasodilatation and reduced cardiac workload. The drug treats a broad range of indications including coronary artery disease, heart failure, hypertension, and cerebral vasospasm.
Very limited commercial opportunity; product is in late maturity with minimal market presence and low headcount requirements.
(NO), which activates guanylate cyclase, resulting in an increase of guanosine 3',5'-monophosphate (cyclic GMP) in smooth muscle and other tissues. This eventually leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in vasodilatation.
Nitrate Vasodilator
Worked on NITROLINGUAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
Safety of Nitroglycerin for Field Treatment of STEMI
Treatment of Suspected Cholelithiasis With Nitroglycerin
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
NITROLINGUAL offers minimal career growth potential given its mature lifecycle stage, approaching loss of exclusivity, and negligible Part D commercial footprint ($36K annual spending). Roles on this product are maintenance-focused and typically serve as stepping stones rather than growth platforms.